These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 30230667)
1. Potassium control in chronic kidney disease: implications for neuromuscular function. Arnold R; Pianta TJ; Pussell BA; Endre Z; Kiernan MC; Krishnan AV Intern Med J; 2019 Jul; 49(7):817-825. PubMed ID: 30230667 [TBL] [Abstract][Full Text] [Related]
2. Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. Furuland H; McEwan P; Evans M; Linde C; Ayoubkhani D; Bakhai A; Palaka E; Bennett H; Qin L BMC Nephrol; 2018 Aug; 19(1):211. PubMed ID: 30134846 [TBL] [Abstract][Full Text] [Related]
3. Association between serum potassium levels and adverse outcomes in chronic kidney disease: the Fukushima CKD cohort study. Tanaka K; Saito H; Iwasaki T; Oda A; Watanabe S; Kanno M; Kimura H; Shimabukuro M; Asahi K; Watanabe T; Kazama JJ Clin Exp Nephrol; 2021 Apr; 25(4):410-417. PubMed ID: 33411113 [TBL] [Abstract][Full Text] [Related]
4. Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice. De Nicola L; Di Lullo L; Paoletti E; Cupisti A; Bianchi S J Nephrol; 2018 Oct; 31(5):653-664. PubMed ID: 29882199 [TBL] [Abstract][Full Text] [Related]
5. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania. Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676 [TBL] [Abstract][Full Text] [Related]
16. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174 [TBL] [Abstract][Full Text] [Related]
17. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Rosano GMC; Tamargo J; Kjeldsen KP; Lainscak M; Agewall S; Anker SD; Ceconi C; Coats AJS; Drexel H; Filippatos G; Kaski JC; Lund L; Niessner A; Ponikowski P; Savarese G; Schmidt TA; Seferovic P; Wassmann S; Walther T; Lewis BS Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):180-188. PubMed ID: 29726985 [TBL] [Abstract][Full Text] [Related]
18. The prevalence of hyperkalemia in the United States. Betts KA; Woolley JM; Mu F; McDonald E; Tang W; Wu EQ Curr Med Res Opin; 2018 Jun; 34(6):971-978. PubMed ID: 29368958 [TBL] [Abstract][Full Text] [Related]
19. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis. Maddirala S; Khan A; Vincent A; Lau K Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676 [TBL] [Abstract][Full Text] [Related]
20. Serum potassium abnormalities in chronic kidney disease: prevalence, patient characteristics and clinical outcomes. Brookes EM; Snider J; Hart GK; Robbins R; Power DA Intern Med J; 2021 Nov; 51(11):1906-1918. PubMed ID: 33314585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]